<protocols>
<search_params/>
<count>82</count>
<protocol>
<id>101</id>
<no id="101">1438-0008</no>
<title>A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined with Standard of Care (Platinum, Etoposide, and Anti-PD-L1) in Patients with Extensive Stage Small Cell Lung Carcinoma</title>
<status>Open</status>
</protocol>
<protocol>
<id>544</id>
<no id="544">2021-GI-01</no>
<title>Evaluation of the Clinical Performance and Safety of an Investigational Fully Covered Biliary Stent with Anti-migration Flaps for the Palliative Treatment of Malignant Biliary Obstruction HANAROSTENTÂ® Biliary Flap Lasso Stent System IDE Study</title>
<status>Open</status>
</protocol>
<protocol>
<id>364</id>
<no id="364">22-01</no>
<title>A Two-Stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel with Placebo in the Treatment of Female Participants with Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)</title>
<status>Open</status>
</protocol>
<protocol>
<id>287</id>
<no id="287">22-151-07</no>
<title>Registry of Patients Undergoing Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography Procedures Using the Slim Endoscopes</title>
<status>Open</status>
</protocol>
<protocol>
<id>288</id>
<no id="288">24-015-01</no>
<title>Artificial Intelligence in Endoscopic Ultrasound</title>
<status>Open</status>
</protocol>
<protocol>
<id>765</id>
<no id="765">61186372NSC2012</no>
<title>A Phase 2B, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based hemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS </title>
<status>Open</status>
</protocol>
<protocol>
<id>804</id>
<no id="804">630-2000-01</no>
<title>An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial</title>
<status>Open</status>
</protocol>
<protocol>
<id>405</id>
<no id="405">90301900NSC2001</no>
<title>Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>26</id>
<no id="26">A012103</no>
<title>OptimICE-pCR: De-Escalation of Therapy in Early-Staging TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy</title>
<status>Open</status>
</protocol>
<protocol>
<id>90</id>
<no id="90">ABX464-107-DHI</no>
<title>A Randomized, Double-Blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis</title>
<status>Open</status>
</protocol>
<protocol>
<id>1044</id>
<no id="1044">AUTO1-OS1</no>
<title>Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia</title>
<status>Open</status>
</protocol>
<protocol>
<id>143</id>
<no id="143">BB2121-EAP-001</no>
<title>Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release</title>
<status>Open</status>
</protocol>
<protocol>
<id>139</id>
<no id="139">BDTX-1535-101</no>
<title>A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>85</id>
<no id="85">BEEPER</no>
<title>Prospective Randomized Comparison of En Bloc Versus Piecemeal Resection of Barrett Neoplasms of Esophagus Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection</title>
<status>Open</status>
</protocol>
<protocol>
<id>104</id>
<no id="104">BH-BS006-001</no>
<title>A Phase 1, Open-Label Study of BS006, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors</title>
<status>Open</status>
</protocol>
<protocol>
<id>225</id>
<no id="225">BILE-DUCT-STONES-REGISTRY</no>
<title>Registry of Patients Undergoing Endoscopic Management of Bile Duct Stones</title>
<status>Open</status>
</protocol>
<protocol>
<id>284</id>
<no id="284">C5041047</no>
<title>A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients with Ulcerative Colitis (ENDEAVOUR-UC)</title>
<status>Open</status>
</protocol>
<protocol>
<id>264</id>
<no id="264">CLIN-AND-HISTO-OUTCOMES-ESD</no>
<title>Clinical and Histological Outcomes of Patients with Barrett's Esophagus Undergoing Endoscopic Submucosal Dissection</title>
<status>Open</status>
</protocol>
<protocol>
<id>21</id>
<no id="21">CLN-617-001</no>
<title>A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab In Patients with Advanced Solid Tumors </title>
<status>Open</status>
</protocol>
<protocol>
<id>103</id>
<no id="103">D8535C00001</no>
<title>A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease</title>
<status>Open</status>
</protocol>
<protocol>
<id>1</id>
<no id="1">DRTEST</no>
<status>Open</status>
</protocol>
<protocol>
<id>2</id>
<no id="2">DRTEST2</no>
<status>Open</status>
</protocol>
<protocol>
<id>228</id>
<no id="228">ECHOENDO</no>
<title>Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope.</title>
<status>Open</status>
</protocol>
<protocol>
<id>565</id>
<no id="565">EIK1001-005</no>
<title>A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>229</id>
<no id="229">EMPOWER-IFX-CEP</no>
<title>A Non-Interventional Chart Review of EMPOWER CEP: Utility of a Precision-Guided Dosing Laboratory Developed Diagnostic Test for the Dose Optimization of Infliximab in a Real-World Inflammatory Bowel Disease Population</title>
<status>Open</status>
</protocol>
<protocol>
<id>99</id>
<no id="99">EPOCH</no>
<title>Randomized Trial of EUS-Guided Celiac Plexus Block vs. Sham for Palliation of Pain in Chronic Pancreatitis</title>
<status>Open</status>
</protocol>
<protocol>
<id>209</id>
<no id="209">FCBTR-CURRENT</no>
<title>Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research</title>
<status>Open</status>
</protocol>
<protocol>
<id>87</id>
<no id="87">GASTROJEJUNOSTOMY</no>
<title>Randomized Trial Comparing Endoscopic Ultrasound-guided Gastrojejunostomy and Surgical Gastrojejunostomy in Gastric Outlet Obstruction</title>
<status>Open</status>
</protocol>
<protocol>
<id>226</id>
<no id="226">GB-DRAINAGE</no>
<title>Registry of Patients Undergoing EUS-Guided Gallbladder Drainage</title>
<status>Open</status>
</protocol>
<protocol>
<id>766</id>
<no id="766">GCT1046-06</no>
<title>A Prospective, Open-label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)</title>
<status>Open</status>
</protocol>
<protocol>
<id>853</id>
<no id="853">GCT1184-02</no>
<title>A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice in Patients with Platinum Resistant Ovarian Cancer </title>
<status>Open</status>
</protocol>
<protocol>
<id>66</id>
<no id="66">GS-US-595-6184</no>
<title>A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy</title>
<status>Open</status>
</protocol>
<protocol>
<id>93</id>
<no id="93">HBOT-UC</no>
<title>Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial</title>
<status>Open</status>
</protocol>
<protocol>
<id>67</id>
<no id="67">HCRN-BRE20-468</no>
<title>A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)</title>
<status>Open</status>
</protocol>
<protocol>
<id>230</id>
<no id="230">IBD</no>
<title>Evaluating Multiple Combination Therapy of Biologics and Small Molecules for Ulcerative Colitis and Crohn's Disease.</title>
<status>Open</status>
</protocol>
<protocol>
<id>43</id>
<no id="43">ICONIC-A031702</no>
<title>A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)</title>
<status>Open</status>
</protocol>
<protocol>
<id>68</id>
<no id="68">IDE397-001</no>
<title>An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors</title>
<status>Open</status>
</protocol>
<protocol>
<id>23</id>
<no id="23">IMCGP100-203</no>
<title>Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)</title>
<status>Open</status>
</protocol>
<protocol>
<id>847</id>
<no id="847">INCA34176-357</no>
<title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease</title>
<status>Open</status>
</protocol>
<protocol>
<id>564</id>
<no id="564">IOV-EAP-402</no>
<title>Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release </title>
<status>Open</status>
</protocol>
<protocol>
<id>70</id>
<no id="70">IOV-GM1-201</no>
<title>A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>71</id>
<no id="71">IOV-MEL-301</no>
<title>A Phase 3, Multicenter, Randomized, Open-Label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma</title>
<status>Open</status>
</protocol>
<protocol>
<id>205</id>
<no id="205">ISI-ION-003</no>
<title>A Multi-Center, Prospective, Single-Arm, Observational Study to Evaluate Real-World Outcomes for the Shape-Sensing Ion Endoluminal System</title>
<status>Open</status>
</protocol>
<protocol>
<id>142</id>
<no id="142">JCAR017-EAP-001</no>
<title>Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.</title>
<status>Open</status>
</protocol>
<protocol>
<id>111</id>
<no id="111">KISIMA-02</no>
<title>A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)</title>
<status>Open</status>
</protocol>
<protocol>
<id>404</id>
<no id="404">M22-003</no>
<title>A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2)</title>
<status>Open</status>
</protocol>
<protocol>
<id>113</id>
<no id="113">MAJESTEC-9</no>
<title>A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide</title>
<status>Open</status>
</protocol>
<protocol>
<id>484</id>
<no id="484">MK-2870-010</no>
<title>An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer.</title>
<status>Open</status>
</protocol>
<protocol>
<id>95</id>
<no id="95">MK-7240-001</no>
<title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis.</title>
<status>Open</status>
</protocol>
<protocol>
<id>271</id>
<no id="271">MK7240-008</no>
<title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn's Disease.</title>
<status>Open</status>
</protocol>
<protocol>
<id>407</id>
<no id="407">ML44719</no>
<title>A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis</title>
<status>Open</status>
</protocol>
<protocol>
<id>39</id>
<no id="39">MODERNA-MRNA-4157-P201</no>
<title>A Phase 2 Randomized Study of Adjuvant Immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942).</title>
<status>Open</status>
</protocol>
<protocol>
<id>138</id>
<no id="138">MRNA-4157-P101</no>
<title>A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors</title>
<status>Open</status>
</protocol>
<protocol>
<id>134</id>
<no id="134">NRG-BR007</no>
<title>A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>37</id>
<no id="37">NRG-BR008</no>
<title>A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)</title>
<status>Open</status>
</protocol>
<protocol>
<id>114</id>
<no id="114">NRG-BR009</no>
<title>A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)</title>
<status>Open</status>
</protocol>
<protocol>
<id>27</id>
<no id="27">NRG-GI008</no>
<title>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease</title>
<status>Open</status>
</protocol>
<protocol>
<id>1224</id>
<no id="1224">NRG-GY036</no>
<title>Phase 3 Trial of 1 vs. 2 Years of Maintenance Olaparib, with or without Bevacizumna, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRB+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy.</title>
<status>Open</status>
</protocol>
<protocol>
<id>464</id>
<no id="464">NRG-LU007</no>
<title>Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial</title>
<status>Open</status>
</protocol>
<protocol>
<id>465</id>
<no id="465">NRG-LU008</no>
<title>Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer</title>
<status>Open</status>
</protocol>
<protocol>
<id>116</id>
<no id="116">OBX115-23-01</no>
<title>A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors</title>
<status>Open</status>
</protocol>
<protocol>
<id>764</id>
<no id="764">OH-BIOREPOSITORY</no>
<title>Orlando Health Biorepository </title>
<status>Open</status>
</protocol>
<protocol>
<id>286</id>
<no id="286">P-23-003-BARRETTS-CAD</no>
<title>Data Collection for Development of Computer-Aided Detection and Diagnosis (CAD) System for Barrett's Esophagus </title>
<status>Open</status>
</protocol>
<protocol>
<id>265</id>
<no id="265">PANCREATIC-FLUID-COLLECT-REG</no>
<title>Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections.</title>
<status>Open</status>
</protocol>
<protocol>
<id>84</id>
<no id="84">PATENT-B</no>
<title>Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture- Bowel</title>
<status>Open</status>
</protocol>
<protocol>
<id>86</id>
<no id="86">PATENT-E</no>
<title>Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture- Esophagus</title>
<status>Open</status>
</protocol>
<protocol>
<id>117</id>
<no id="117">PRESERVE-003</no>
<title>Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors</title>
<status>Open</status>
</protocol>
<protocol>
<id>147</id>
<no id="147">PVP-22IC04</no>
<title>An Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Efficacy, and Physician Satisfaction of Two Different Doses of Bludigo (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency.</title>
<status>Open</status>
</protocol>
<protocol>
<id>146</id>
<no id="146">PVP-22IC05</no>
<title>An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo; (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency.</title>
<status>Open</status>
</protocol>
<protocol>
<id>41</id>
<no id="41">R3767-ONC-2011</no>
<title>A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma</title>
<status>Open</status>
</protocol>
<protocol>
<id>100</id>
<no id="100">RABI-767-201</no>
<title>A Phase 2A, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants with Predicted Severe Acute Pancreatitis</title>
<status>Open</status>
</protocol>
<protocol>
<id>122</id>
<no id="122">RECTAL-INDO-PAN-CYSTS</no>
<title>Randomized Trial of Rectal Indomethacin to Prevent Acute Pancreatitis in Patients Undergoing Endoscopic Ultrasound-guided Fine Needle Aspiration of Pancreatic Cysts</title>
<status>Open</status>
</protocol>
<protocol>
<id>188</id>
<no id="188">RTOG-1216</no>
<title>Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck</title>
<status>Open</status>
</protocol>
<protocol>
<id>136</id>
<no id="136">RYZ101-101</no>
<title>Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)</title>
<status>Open</status>
</protocol>
<protocol>
<id>224</id>
<no id="224">SINGLE-SITE-SURGERY-DATABASE</no>
<title>Laparoendoscopic and Robotic Single Site Surgery Database</title>
<status>Open</status>
</protocol>
<protocol>
<id>266</id>
<no id="266">SRS-CHART-REVIEW</no>
<title>Evaluation of Treatment Outcomes Following Stereotactic Radiosurgery (SRS) for Brain Metastases</title>
<status>Open</status>
</protocol>
<protocol>
<id>145</id>
<no id="145">STREAM</no>
<title>Optilume Post Approval Clinical Evaluation of Andrology Parameters</title>
<status>Open</status>
</protocol>
<protocol>
<id>120</id>
<no id="120">TSCAN-002</no>
<title>A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-Positive Locally Advanced (Unresectable) or Metastatic Solid Tumors</title>
<status>Open</status>
</protocol>
<protocol>
<id>129</id>
<no id="129">TSCAN-003</no>
<title>Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors.</title>
<status>Open</status>
</protocol>
<protocol>
<id>644</id>
<no id="644">U0755</no>
<title>SpaceIT Hydrogel System for Perirectal Spacing in Subjects with Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT)</title>
<status>Open</status>
</protocol>
<protocol>
<id>133</id>
<no id="133">ULI-EAP-100</no>
<title>Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies</title>
<status>Open</status>
</protocol>
<protocol>
<id>270</id>
<no id="270">VEDOLIZUMAB-3043</no>
<title>A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy with Intravenous Vedolizumab and Oral Upadacitinib Compared with Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants with Moderately to Severely Active Crohn's Disease. </title>
<status>Open</status>
</protocol>
<sipVersion>2025.1 Build 10</sipVersion>
<copyright> <a href="https://advarra.com" target="_blank">&copy; 2025 Advarra, Inc.</a> </copyright>
</protocols>